To evaluate the long-term frequency of disease remissions and the progression of joint damage in patients with early rheumatoid arthritis ( RA ) who were initially randomized to 2 years of treatment with either a combination of 3 disease-modifying antirheumatic drugs ( DMARDs ) or a single DMARD .
